Abstract
Frailty is now defined as a clinical entity and potentially responsive to medications. This article reviews the drugs available and those under development. While, at present, exercise is the primary therapy, it is expected over the next decade that numerous drugs will be available to treat components of the frailty syndrome.
Current Pharmaceutical Design
Title: Developing Novel Therapeutic Approaches to Frailty
Volume: 15 Issue: 29
Author(s): John E. Morley
Affiliation:
Abstract: Frailty is now defined as a clinical entity and potentially responsive to medications. This article reviews the drugs available and those under development. While, at present, exercise is the primary therapy, it is expected over the next decade that numerous drugs will be available to treat components of the frailty syndrome.
Export Options
About this article
Cite this article as:
Morley E. John, Developing Novel Therapeutic Approaches to Frailty, Current Pharmaceutical Design 2009; 15 (29) . https://dx.doi.org/10.2174/138161209789105045
DOI https://dx.doi.org/10.2174/138161209789105045 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy The Role of Tec Family Kinases in Inflammatory Processes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice
CNS & Neurological Disorders - Drug Targets Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology HLA-DR: Molecular Insights and Vaccine Design
Current Pharmaceutical Design Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
Current Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Current Neuropharmacology Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets